Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,709 | N/A | -6,261 | N/A | N/A |
| Depreciation Amortization | 8 | N/A | 11 | N/A | N/A |
| Accounts receivable | 141 | N/A | -140 | N/A | N/A |
| Accounts payable and accrued liabilities | 245 | N/A | 49 | N/A | N/A |
| Other Working Capital | 395 | N/A | -89 | N/A | N/A |
| Other Operating Activity | -80 | 0 | 680 | 0 | 0 |
| Operating Cash Flow | $-4,000 | $N/A | $-5,750 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5 | N/A | -3 | N/A | N/A |
| Purchase Of Investment | -8 | N/A | 4 | N/A | N/A |
| Investing Cash Flow | $-13 | $N/A | $1 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,366 | N/A | 4,317 | N/A | N/A |
| Other Financing Activity | -65 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $1,301 | $N/A | $4,317 | $N/A | $N/A |
| Beginning Cash Position | 3,378 | N/A | 2,640 | N/A | N/A |
| End Cash Position | 666 | N/A | 1,208 | N/A | N/A |
| Net Cash Flow | $-2,712 | $N/A | $-1,432 | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,000 | N/A | -5,750 | N/A | N/A |
| Capital Expenditure | -5 | N/A | -3 | N/A | N/A |
| Free Cash Flow | -4,005 | 0 | -5,753 | 0 | 0 |